Results 41 to 50 of about 2,906,691 (234)

Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta‐analysis

Colorectal Disease, 2020
Peritoneal metastases from colorectal cancer confer the worst survival among all metastatic sites. The adoption of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) can offer selected patients with isolated colorectal ...
V. Narasimhan, Sabrina Tan, Joseph C. H. Kong, T. Pham, M. Michael, R. Ramsay, S. Warrier, A. Heriot   +7 more
semanticscholar   +1 more source

Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy [PDF]

, 2010
BACKGROUND: Peritoneal carcinomatosis (PC) from gastric cancer has long been regarded a terminal disease with a short median survival. New locoregional therapeutic approaches combining cytoreductive surgery with perioperative intraperitoneal chemotherapy
Association Française de Chirurgie (AFC), B. Mansvelt, C. Arvieux, D. Elias, E. Cotte, F. Boutitie, F. Quenet, F.Noel Gilly, G. Lorimier, J.Marc Bereder, O. Glehen   +10 more
core   +2 more sources

Carcinoembryonic antigen‐specific, fluorescent image‐guided cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer

British Journal of Surgery, 2020
This multicentre pilot study investigated the role of peroperative carcinoembryonic antigen (CEA)‐specific fluorescence imaging during cytoreductive surgery–hyperthermic intraperitoneal chemotherapy surgery in peritoneal metastasized colorectal cancer. A
D. Schaap, K. S. de Valk, M. Deken, R. Meijer, J. Burggraaf, A. Vahrmeijer, M. Kusters   +6 more
semanticscholar   +1 more source

Intraperitoneal chemotherapy for peritoneal metastases : an expert opinion

, 2020
Introduction: The rationale for intraperitoneal (IP) drug delivery for patients with peritoneal metastases (PM) is based on the pharmacokinetic advantage resulting from the peritoneal-plasma barrier, and on the potential to adequately treat small, poorly
Braet, Helena, Ceelen, Wim, Remaut, Katrien, Van Ramshorst, Gabrielle, Willaert, Wouter   +4 more
core   +1 more source

In Vivo CRISPR Screening Identifies the Glutamate Receptor GRIA2 as Promoting Peritoneal Metastasis of Gastric Cancer via Calcium‐Dependent β‐Catenin Activation

Advanced Science, EarlyView.
We identified GRIA2 as a critical driver of gastric cancer peritoneal metastasis through in vivo CRISPR screening. Mechanistically, GRIA2‐mediated calcium influx inhibits GSK3β and activates Wnt/β‐catenin signaling, driven by glutamate from cancer‐associated fibroblasts.
Jie Sun, Xu Yang, Wenchao Jiang, Chengbo Ji, Yingying Wu, Haoyu Sun, Xinyou Liu, Masami Yamamoto, Tetsuya Tsukamoto, Sachiyo Nomura, Junjie Zhao, Yuanyuan Ruan, Haojie Li, Xuefei Wang   +13 more
wiley   +1 more source

Cytoreductive Surgery and Peritonectomy Procedures [PDF]

Indian Journal of Surgical Oncology, 2016
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has become widely accepted as an effective method of treating peritoneal metastases (PM) from various cancers. CRS performed with the goal of removing all the macroscopic disease and comprises of peritonectomy procedures and visceral resections.
Sanket S, Mehta, Aditi, Bhatt, Olivier, Glehen   +2 more
openaire   +2 more sources

Treatment of PERItoneal disease in Stomach Cancer with cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy: PERISCOPE I initial results

British Journal of Surgery, 2020
The role of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer is unknown. This non‐randomized dose‐finding phase I–II study was designed to assess the safety and feasibility of HIPEC, following ...
R. T. van der Kaaij, E. Wassenaar, W. Koemans, K. Sikorska, C. Grootscholten, M. Los, A. Huitema, J. Schellens, A. Veenhof, K. Hartemink, A. Aalbers, B. van Ramshorst, D. Boerma, H. Boot, J. V. van Sandick   +14 more
semanticscholar   +1 more source

Complex Genetic Architecture in RASopathies: Constitutional PTPN11 and Mosaic RIT1 Pathogenic Variants Underlying Severe Noonan Syndrome With Adult‐Onset Acute Myeloid Leukemia

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Noonan syndrome (NS) is a genetically heterogeneous disorder characterized by a broad spectrum of clinical features resulting from dysregulation of the RAS/MAPK pathway. Although complex genotypes are increasingly recognized in NS, cases harboring two distinct pathogenic variants in different NS genes remain extremely rare.
Francesco Prevedello, Dario Seif Ali, Chiara Piccolo, Chiara Rigon, Monica Forzan, Elena Tacchetto, Roberta Palmitessa, Davide Calosci, Leonardo Salviati, Carmela Gurrieri, Eva Trevisson   +10 more
wiley   +1 more source

A preclinical mouse model mimicking the ovarian cancer‐induced estrogen deficiency‐depression axis

Animal Models and Experimental Medicine, EarlyView.
A preclinical mouse model of ovarian cancer–related depression was developed by combining intraperitoneal tumor cell injection, ovariectomy, and chronic restraint stress. The model replicates key clinical features including estrogen deficiency, depressive‐like behaviors, and tumor progression, and provides a reliable tool for studying the endocrine ...
Jiamin Liu, Yafei Yang, Chunxi Liu, Danting Wen, Tingyu Zhao, Ping Xie, Jing Xiao   +6 more
wiley   +1 more source

Morbidity and Mortality Rates Following Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Compared With Other High-Risk Surgical Oncology Procedures

JAMA Network Open, 2019
Key Points Question What are the morbidity and mortality of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) compared with other major oncologic surgical procedures?
J. Foster, R. Sleightholm, Asish Patel, V. Shostrom, B. Hall, B. Neilsen, D. Bartlett, Lynette M. Smith   +7 more
semanticscholar   +1 more source